Cytomx Therapeutics Inc SEC Filings

CytomX Therapeutics (CTMX) reported Q3 2025 results marked by lower collaboration revenue and a quarterly loss as it reprioritized programs and completed a major equity raise. Revenue was $5.963 million, down from $33.432 million a year ago, reflecting wind-downs and timing across partnerships. The company posted a net loss of $14.229 million versus income of $5.736 million in Q3 2024.

Year to date, revenue totaled $75.538 million and net income was $9.142 million, aided by recognition of deferred revenue earlier in 2025. Cash and cash equivalents were $34.185 million and short-term investments $109.441 million at September 30, 2025. Total assets rose to $158.254 million and stockholders’ equity improved to $107.389 million, supported by a May underwritten offering of 76,923,076 shares at $1.30 per share for $93.4 million net proceeds.

Deferred revenue declined to $27.916 million, with remaining balances primarily tied to Astellas ($7.2 million), Moderna ($9.3 million) and Regeneron ($11.4 million). The company executed a restructuring in January (approximately 40% workforce reduction; $2.8 million charges) and is prioritizing CX‑2051 (EpCAM ADC) and CX‑801 (IFNα2b) while continuing multi-partner collaborations.

CytomX Therapeutics (CTMX) filed a Form 4 reporting a stock option grant to its Chief Business Officer, Rachael Lester. The award covers 650,000 options to buy common stock at an exercise price of $3.74 per share, granted on 10/20/2025.

Per the vesting terms, 25% of the shares vest on the one-year anniversary of October 20, 2025, with the remainder vesting in equal monthly installments so that the grant is fully vested on the fourth anniversary. The options expire on 10/19/2035. Ownership is reported as Direct (D).

CytomX Therapeutics (CTMX) filed a Form 3 initial statement of beneficial ownership for its Chief Business Officer, Rachael Lester. The filing states that no securities are beneficially owned.

The reported event date is 10/20/2025. The form was signed by Christopher Ogden as attorney-in-fact, referencing Exhibit 24.1 (Power of Attorney).

CytomX Therapeutics insider grant to Chief Medical Officer

Yu-Waye Chu, Chief Medical Officer of CytomX Therapeutics, acquired equity awards on 09/26/2025 consisting of a stock option to purchase 87,500 shares of common stock at an exercise price of $2.90 and 43,750 Performance Stock Units (PSUs), each PSU representing one contingent share. The option vests monthly at 1/48th beginning on the Vesting Commencement Date of 09/26/2025 and becomes fully vested on the fourth anniversary if the reporting person remains in service. The PSUs vest in three tranches, with 1/3 vesting upon achievement of each of three specified clinical milestones, subject to continued service. All reported holdings are direct.

CytomX Therapeutics (CTMX) Chief Financial Officer Christopher Ogden reported option and performance‑unit awards on Sept 26, 2025. He was granted a stock option to buy 78,250 shares at a $2.90 exercise price that vests monthly over four years beginning Sept 26, 2025, and 39,150 Performance Stock Units (PSUs) that vest in three tranches tied to clinical milestones, each PSU convertible into one share on vesting. Following these awards, Mr. Ogden beneficially owns 78,250 option shares and 39,150 PSUs, all held directly. The option expires Sept 25, 2035. The filing is signed Sept 30, 2025.

Marcia Belvin, SVP and Chief Scientific Officer of CytomX Therapeutics (CTMX), was granted equity awards on 09/26/2025. The filing reports a stock option to purchase 36,300 shares with an exercise price of $2.90 and 18,150 Performance Stock Units (PSUs) that convert to one share each upon vesting. The option vests monthly at 1/48th beginning on the Vesting Commencement Date of 09/26/2025, reaching full vesting on the fourth anniversary if service continues. The PSUs vest in three equal tranches upon achievement of specified clinical milestones, subject to continued service. The Form 4 was signed by an attorney-in-fact on 09/30/2025.

Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report a shared beneficial ownership stake of 9,680,185 shares in CytomX Therapeutics, representing 5.9% of the outstanding common stock based on 164,912,906 shares outstanding. The Master Fund directly holds the shares, while Perceptive Advisors, as investment manager, and Mr. Edelman, as managing member, may be deemed to beneficially own those shares. All three reporting persons disclose no sole voting or dispositive power and shared voting and dispositive power over the reported shares.